JCM
CRL icon

Jacobi Capital Management’s Charles River Laboratories CRL Stock Holding History

Jacobi Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-53
Closed -$22K – 595
2021
Q3 		$22K Buy
53
+28
+112% +$11.6K ﹤0.01% 840
2021
Q2 		$9K Hold
25
– – ﹤0.01% 1047
2021
Q1 		$7K Hold
25
– – ﹤0.01% 1048
2020
Q4 		$6K Hold
25
– – ﹤0.01% 961
2020
Q3 		$6K Buy
+25
New +$5.19K ﹤0.01% 898

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobi Capital Management's CRL Position: Q4 2021 in Review

Jacobi Capital Management sold out of Charles River Laboratories (CRL) in Q4 2021, closing a stake of 53 shares — an estimated $22K sold.

Jacobi Capital Management first reported a position in CRL in Q3 2020 and held it in 5 quarters. The position peaked at $22K in Q3 2021. 707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

  • Jacobi Capital Management reported no remaining Charles River Laboratories position as of Q4 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 53 Charles River Laboratories shares in Q4 2021, an estimated $22K.
  • Jacobi Capital Management first reported a position in Charles River Laboratories in Q3 2020 and held it in 5 quarters.
  • Jacobi Capital Management's Charles River Laboratories position peaked at $22K in Q3 2021.
  • 707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.